FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to pharmaceutical industry and dermatology, and is a topical pharmaceutical formulation for the treatment of EGFR inhibitors induced acneiform dermatitis comprising at least 0.02 % berberine or a biologically equivalent analog of berberine such as palmate, and a component selected from group consisting of water, methanol, ethanol and dimethylsulfoxide, wherein berberine or a biologically equivalent analogue of berberine being the primary pharmaceutically active component.
EFFECT: invention provides a wider range of agents for the treatment of EGFR inhibitors induced acneiform dermatitis.
4 cl, 2 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS CONTAINING BERBERINE OR ITS ANALOGUES FOR TREATING SKIN DISEASES RELATED TO ROSACEA OR BLUSH | 2010 |
|
RU2533458C2 |
| THERAPEUTIC USE OF MEDICINAL FORMS OF BERBERINE | 2016 |
|
RU2733743C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF SKIN DISEASES AND CONDITIONS CONTAINING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDROQUINOLINE | 2012 |
|
RU2630978C2 |
| METHOD FOR TREATING DISEASES AND CONDITIONS OF THE EYE | 2012 |
|
RU2667645C1 |
| THERAPEUTIC AGENT FOR INHIBITION OF PHOSPHODIESTERASE AND ASSOCIATED PATHOLOGICAL DISORDERS | 2018 |
|
RU2815010C2 |
| METHOD OF PREPARING WATER-SOLUBLE PHARMACEUTICAL COMPOSITION BASED ON BERBERINE | 2023 |
|
RU2814497C1 |
| METHOD OF TREATMENT OF ROSACEA | 2020 |
|
RU2811956C2 |
| PHARMACEUTICAL CREAM COMPOSITION OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA | 2012 |
|
RU2648439C2 |
| L-SERINE APPLICABLE AS THERAPEUTIC AGENT FOR PREVENTING AND/OR TREATING INFLAMMATORY SKIN RESPONSES | 2010 |
|
RU2554482C2 |
| METHOD OF RADIOINDUCED SKIN REACTIONS TREATMENT | 2022 |
|
RU2796754C1 |
